Home LiteratureArticle Details
PMID: 1630914 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses.

Nucleic acids research ·Vol. 20 ·No. 13 ·1992-07-11 ·Pages 3435-41

Ronen D, Teitz Y, Goldfinger N, Rotter V

Abstract

To facilitate the purification of wild type p53 protein, we established a recombinant p53 vaccinia viral expression system. Using this efficient eukaryotic expression vector, we found that the expressed p53 proteins retained their specific structural characteristics. A comparison between wild type and mutant p53 proteins showed the conservation of the typical subcellular localization and the expression of specific antigenic determinants. Furthermore, wild type p53 exhibited a typical binding with large T antigen, whereas no binding was detected with mutant p53. Both wild type and mutant p53 proteins were highly stable and constituted 5-7% of total protein expressed in the infected cells. These expression recombinant viruses offer a simple, valuable system for the purification of wild type and mutant p53 proteins that are expressed abundantly in eukaryotic cells.

MeSH Terms
Antigens, Viral, Tumor/metabolism Cloning, Molecular/methods Fluorescent Antibody Technique HeLa Cells Humans Mutation/genetics Recombinant Proteins/biosynthesis,metabolism Tumor Suppressor Protein p53/biosynthesis,genetics,metabolism Vaccinia virus/genetics
Chemicals
Antigens, Viral, Tumor Recombinant Proteins Tumor Suppressor Protein p53
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Ronen D
Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Teitz Y
Goldfinger N
Rotter V
References (62)
62 references, click to expand
  1. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate.
    Oncogene. 1991 Oct;6(10):1799-805 PMID: 1923505
  2. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
    Science. 1990 Aug 31;249(4972):1049-51 PMID: 2144364
  3. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
    Cancer Res. 1991 Oct 1;51(19):5232-7 PMID: 1717142
  4. p53 mutations in colorectal cancer.
    Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9 PMID: 1699228
  5. Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells.
    Nature. 1991 Jan 31;349(6308):429-31 PMID: 1671528
  6. Mutant p53 proteins bind DNA abnormally in vitro.
    Oncogene. 1991 Jan;6(1):131-6 PMID: 1846954
  7. Involvement of wild-type p53 protein in the cell cycle requires nuclear localization.
    Cell Growth Differ. 1991 Dec;2(12):661-7 PMID: 1809377
  8. Involvement of wild-type p53 in pre-B-cell differentiation in vitro.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8982-6 PMID: 1924360
  9. p53 mutations in human cancers.
    Science. 1991 Jul 5;253(5015):49-53 PMID: 1905840
  10. Endogenous HeLa p53 proteins are easily detected in HeLa cells transfected with mouse deletion mutant p53 gene.
    Oncogene. 1991 Aug;6(8):1363-5 PMID: 1886712
  11. The p53 tumour suppressor gene.
    Nature. 1991 Jun 6;351(6326):453-6 PMID: 2046748
  12. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.
    Genes Dev. 1991 Feb;5(2):151-9 PMID: 1995413
  13. Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein.
    Mol Cell Biol. 1991 Jan;11(1):582-5 PMID: 1986251
  14. Genetic mechanisms of tumor suppression by the human p53 gene.
    Science. 1990 Dec 14;250(4987):1576-80 PMID: 2274789
  15. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells.
    Oncogene. 1990 Nov;5(11):1707-11 PMID: 2267137
  16. Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. II. Requirement for cell cycle progression.
    Oncogene. 1990 Nov;5(11):1701-6 PMID: 2267136
  17. Cancer. A deadly inheritance.
    Nature. 1990 Dec 20-27;348(6303):681-2 PMID: 2259380
  18. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis.
    Mol Cell Biol. 1990 Dec;10(12):6565-77 PMID: 2247074
  19. p53 functions as a cell cycle control protein in osteosarcomas.
    Mol Cell Biol. 1990 Nov;10(11):5772-81 PMID: 2233717
  20. Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins.
    J Biol Chem. 1989 Oct 25;264(30):18019-23 PMID: 2553699
  21. Mutations in the p53 gene occur in diverse human tumour types.
    Nature. 1989 Dec 7;342(6250):705-8 PMID: 2531845
  22. Processing and secretion of nerve growth factor: expression in mammalian cells with a vaccinia virus vector.
    Mol Cell Biol. 1988 Jun;8(6):2456-64 PMID: 3405211
  23. High expression of functional adenovirus DNA polymerase and precursor terminal protein using recombinant vaccinia virus.
    Nucleic Acids Res. 1988 Mar 25;16(6):2431-44 PMID: 3362670
  24. Mouse p53 blocks SV40 DNA replication in vitro and downregulates T antigen DNA helicase activity.
    Oncogene. 1988 Oct;3(4):405-13 PMID: 2856250
  25. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.
    Proc Natl Acad Sci U S A. 1985 Feb;82(3):790-4 PMID: 2858093
  26. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.
    Mol Cell Biol. 1988 Feb;8(2):531-9 PMID: 2832726
  27. Mouse p53 inhibits SV40 origin-dependent DNA replication.
    Nature. 1987 Oct 1-7;329(6138):458-60 PMID: 2821401
  28. Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex.
    J Virol. 1986 Sep;59(3):574-83 PMID: 3016321
  29. Conserved TAAAT motif in vaccinia virus late promoters: overlapping TATA box and site of transcription initiation.
    EMBO J. 1986 May;5(5):1071-6 PMID: 3013615
  30. Immunologically distinct p53 molecules generated by alternative splicing.
    Mol Cell Biol. 1986 Sep;6(9):3232-9 PMID: 3023970
  31. Meth A fibrosarcoma cells express two transforming mutant p53 species.
    Oncogene. 1988 Sep;3(3):313-21 PMID: 3060794
  32. Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses.
    Virology. 1988 Oct;166(2):339-49 PMID: 2459842
  33. Presence of a potent transcription activating sequence in the p53 protein.
    Science. 1990 Aug 31;249(4972):1046-9 PMID: 2144363
  34. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.
    Cell. 1990 Aug 24;62(4):671-80 PMID: 2143698
  35. Suppression of human colorectal carcinoma cell growth by wild-type p53.
    Science. 1990 Aug 24;249(4971):912-5 PMID: 2144057
  36. p53: oncogene or anti-oncogene?
    Genes Dev. 1990 Jan;4(1):1-8 PMID: 2137806
  37. Monoclonal antibodies specific for simian virus 40 tumor antigens.
    J Virol. 1981 Sep;39(3):861-9 PMID: 6169844
  38. Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny.
    Mol Cell Biol. 1982 Apr;2(4):443-9 PMID: 6287239
  39. Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents.
    J Virol. 1981 Apr;38(1):336-46 PMID: 6264107
  40. Non-producer human cells induced by murine sarcoma virus.
    Int J Cancer. 1975 Jan 15;15(1):23-9 PMID: 165148
  41. A new technique for the assay of infectivity of human adenovirus 5 DNA.
    Virology. 1973 Apr;52(2):456-67 PMID: 4705382
  42. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  43. Monoclonal antibody analysis of p53 expression in normal and transformed cells.
    J Virol. 1986 Aug;59(2):444-52 PMID: 2426467
  44. Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule.
    Mol Cell Biol. 1985 Jan;5(1):127-32 PMID: 2580227
  45. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia.
    Blood. 1989 Nov 15;74(7):2318-24 PMID: 2572286
  46. p53: a frequent target for genetic abnormalities in lung cancer.
    Science. 1989 Oct 27;246(4929):491-4 PMID: 2554494
  47. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen.
    Cell. 1989 May 5;57(3):379-92 PMID: 2541911
  48. Wild-type p53 can inhibit oncogene-mediated focus formation.
    Proc Natl Acad Sci U S A. 1989 Nov;86(22):8763-7 PMID: 2530586
  49. Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines: effects of protein sequence and intracellular environment.
    Mol Cell Biol. 1989 Aug;9(8):3385-92 PMID: 2529426
  50. The p53 proto-oncogene can act as a suppressor of transformation.
    Cell. 1989 Jun 30;57(7):1083-93 PMID: 2525423
  51. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
    Science. 1989 Apr 14;244(4901):217-21 PMID: 2649981
  52. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6783-7 PMID: 2771957
  53. Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.
    J Virol. 1988 Jan;62(1):176-80 PMID: 3334743
  54. p53 and DNA polymerase alpha compete for binding to SV40 T antigen.
    Nature. 1987 Oct 1-7;329(6138):456-8 PMID: 3309672
  55. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines.
    Mol Cell Biol. 1987 Aug;7(8):2863-9 PMID: 3313006
  56. Expression of p53 in human leukemia and lymphoma.
    Blood. 1986 Jul;68(1):113-8 PMID: 3521760
  57. Specific interaction between the p53 cellular tumour antigen and major heat shock proteins.
    Nature. 1986 Mar 13-19;320(6058):182-4 PMID: 3513022
  58. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
    EMBO J. 1990 May;9(5):1595-602 PMID: 1691710
  59. Wild type human p53 is antiproliferative in SV40-transformed hamster cells.
    Oncogene. 1990 Jul;5(7):973-80 PMID: 2165234
  60. Transformation by simian virus 40 does not involve the mutational activation of p53 to an oncogenic form.
    Virology. 1990 May;176(1):302-5 PMID: 2158695
  61. The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif.
    Oncogene. 1990 Mar;5(3):423-6 PMID: 2156209
  62. Degradation of nuclear oncoproteins by the ubiquitin system in vitro.
    Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):139-43 PMID: 1846034
Article Info
Journal
Nucleic acids research
Abbr.
Nucleic Acids Res
ISSN
0305-1048
DOI
10.1093/nar/20.13.3435
Published
1992-07-11
Pages
3435-41
Language
English
Region
England
NLM ID
0411011
PMCID
PMC312500
Subset
IM
External Links
PubMed source DOI: 10.1093/nar/20.13.3435 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2